Research · Oct 23, 2026
Reporting and interpreting results: CONSORT, plausibility, absolute effect and applicability
Concept
Publication in a peer-reviewed journal is not an endorsement of the results. Investigators know the limitations of the data better than reviewers and readers and have the obligation to report them. Friedman organizes interpretation around three questions: did the trial work as planned, how do the findings compare with other studies, and what are the clinical implications.
Reporting guidelines
CONSORT gathers the essential items of a randomized trial report: objectives, design, participants, interventions, primary and secondary outcomes, sample size, randomization, blinding, statistical analysis, baseline data, outcomes, harms, limitations and generalizability. The 2001 revised version had 22 items and a flow diagram with the number of participants per group at each stage, which lets the reader check whether the analysis was by intention to treat.
Friedman points to two loosely used terms. “Intention to treat” does not apply when randomized participants were excluded from the analysis, and “modified ITT” is a contradiction. “Per protocol” suggests the analysis preferred by the protocol; Friedman prefers “on treatment” (see intention to treat).
The p value, point estimate and confidence interval should be reported together for the main results.
Publication and reporting bias
Negative trials are published less often. Turner and colleagues compared 74 antidepressant studies registered with the FDA. 31% were not published. In the published literature, 94% of trials appeared positive; in the FDA analysis, 51%.
Chan and colleagues compared protocols and publications of 102 trials approved in Copenhagen. Half of the efficacy outcomes and 65% of the harm outcomes per trial were incompletely reported. According to Friedman, 62% of trials had a discrepancy between the primary outcome in the protocol and the one published.
Did the trial work as planned?
- Baseline comparability: description of randomization and concealment, table of characteristics by group.
- Blinding: many trials do not stay blind from start to finish. Success of blinding should be assessed at the end.
- Adherence and concomitant treatment: compare observed adherence with that assumed in the sample size.
- Limitations: for a neutral result, consider inadequate dose, insufficient technical skill, insufficient power, low adherence, insensitive outcomes and chance.
- Missing data: a worst-case analysis assigns an event to every participant lost from the group with lower incidence and no event to those lost from the other group. If the conclusion holds, it is strengthened.
- Multiple comparisons and composite outcomes: see multiple comparisons and composite outcomes.
Plausibility and consistency
The result should be compatible with the known mechanism of action and with other studies. Credibility increases with the proportion of good-quality independent studies reaching the same conclusion. Confidence intervals allow readers to check whether results of different trials are compatible.
Absolute and relative effect
Presentation changes decisions. Forrow and colleagues presented the same results to 235 physicians as a relative change and as an absolute change. 108 (46%) responded differently, and 90% of these were more inclined to treat after reading the relative change. Naylor and colleagues observed the lowest effectiveness ratings when the result was presented as a number needed to treat. Friedman recommends reporting both absolute and relative effects (see RRR, ARR and NNT).
Applicability
Generalization to the eligible population is direct. Extrapolation to patients who would not meet the inclusion criteria requires judgment. Rothwell lists the determinants of external validity: setting, patient selection, characteristics of the intervention and control, outcomes and adverse events. Further questions include dose-response, class effect and newer versions of devices.
Common errors when reading a paper
- Reading only the abstract and conclusion.
- Accepting the “intention to treat” label without checking the flow diagram.
- Judging the effect by the relative reduction alone.
- Ignoring a discrepancy between the registered and the published outcome.
- Applying the result to patients outside the inclusion criteria without justification.
What to check when reading a trial
- Trial registration and agreement between the registered and published primary outcome.
- Flow diagram with numbers by group at each stage.
- Estimate, confidence interval and absolute effect for the primary outcome.
- Adherence, losses to follow-up and sensitivity analysis for missing data.
- Total number of comparisons made.
- Comparison with other trials and biological plausibility.
- Similarity between the trial population and the patient at hand.
References
- Friedman LM, Furberg CD, DeMets DL, Reboussin DM, Granger CB. Fundamentals of Clinical Trials. 5th ed. Springer; 2015. Chapter 20, Reporting and Interpreting of Results.
- Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357:1191-4. doi: 10.1016/S0140-6736(00)04337-3
- Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252-60. doi: 10.1056/NEJMsa065779
- Chan AW, Hróbjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004;291:2457-65. doi: 10.1001/jama.291.20.2457
- Forrow L, Taylor WC, Arnold RM. Absolutely relative: how research results are summarized can affect treatment decisions. Am J Med. 1992;92:121-4. doi: 10.1016/0002-9343(92)90100-p
- Naylor CD, Chen E, Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med. 1992;117:916-21. doi: 10.7326/0003-4819-117-11-916
- Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet. 2005;365:82-93. doi: 10.1016/S0140-6736(04)17670-8